These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22954106)

  • 1. Myo9B is associated with an increased risk of Barrett's esophagus and esophageal adenocarcinoma.
    Menke V; Van Zoest KP; Moons LM; Pot RG; Siersema PD; Kuipers EJ; Kusters JG
    Scand J Gastroenterol; 2012 Dec; 47(12):1422-8. PubMed ID: 22954106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NcoI TNF-β gene polymorphism and TNF expression are associated with an increased risk of developing Barrett's esophagus and esophageal adenocarcinoma.
    Menke V; van Zoest KP; Moons LM; Hansen B; Pot RG; Siersema PD; Kusters JG; Kuipers EJ
    Scand J Gastroenterol; 2012 Apr; 47(4):378-86. PubMed ID: 22243485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genes of the interleukin-18 pathway are associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma.
    Babar M; Ryan AW; Anderson LA; Segurado R; Turner G; Murray LJ; Murphy SJ; Johnston BT; Comber H; Reynolds JV; McManus R
    Am J Gastroenterol; 2012 Sep; 107(9):1331-41. PubMed ID: 22664470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No association between hOGG1, XRCC1, and XPD polymorphisms and risk of reflux esophagitis, Barrett's esophagus, or esophageal adenocarcinoma: results from the factors influencing the Barrett's adenocarcinoma relationship case-control study.
    Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):736-9. PubMed ID: 18349297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
    Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):727-31. PubMed ID: 18349295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional single-nucleotide polymorphism of epidermal growth factor is associated with the development of Barrett's esophagus and esophageal adenocarcinoma.
    Menke V; Pot RG; Moons LM; van Zoest KP; Hansen B; van Dekken H; Siersema PD; Kusters JG; Kuipers EJ
    J Hum Genet; 2012 Jan; 57(1):26-32. PubMed ID: 22129558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma.
    Moons LM; Kuipers EJ; Rygiel AM; Groothuismink AZ; Geldof H; Bode WA; Krishnadath KK; Bergman JJ; van Vliet AH; Siersema PD; Kusters JG
    Am J Gastroenterol; 2007 Nov; 102(11):2373-9. PubMed ID: 17581270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro.
    De Gottardi A; Dumonceau JM; Bruttin F; Vonlaufen A; Morard I; Spahr L; Rubbia-Brandt L; Frossard JL; Dinjens WN; Rabinovitch PS; Hadengue A
    Mol Cancer; 2006 Oct; 5():48. PubMed ID: 17054793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of methylenetetrahydrofolate reductase C677T-A1298C polymorphisms with risk for esophageal adenocarcinoma, Barrett's esophagus, and reflux esophagitis.
    Ekiz F; Ormeci N; Coban S; Karabulut HG; Aktas B; Tukun A; Tuncali T; Yüksel O; Alkış N
    Dis Esophagus; 2012 Jul; 25(5):437-41. PubMed ID: 21951971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma.
    Casson AG; Zheng Z; Evans SC; Geldenhuys L; van Zanten SV; Veugelers PJ; Porter GA; Guernsey DL
    Cancer; 2005 Aug; 104(4):730-9. PubMed ID: 15971196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
    Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A population-based association study of SNPs of GSTP1, MnSOD, GPX2 and Barrett's esophagus and esophageal adenocarcinoma.
    Murphy SJ; Hughes AE; Patterson CC; Anderson LA; Watson RG; Johnston BT; Comber H; McGuigan J; Reynolds JV; Murray LJ
    Carcinogenesis; 2007 Jun; 28(6):1323-8. PubMed ID: 17277236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-1 RN polymorphism is not associated with Barrett's esophagus and esophageal adenocarcinoma.
    Moons LM; Siersema PD; Kuipers EJ; van Vliet AH; Kusters JG
    Am J Gastroenterol; 2005 Dec; 100(12):2818. PubMed ID: 16393246
    [No Abstract]   [Full Text] [Related]  

  • 14. Toll-like Receptor 2 Signalling and the Lysosomal Machinery in Barrett's Esophagus.
    Verbeek RE; Siersema PD; Vleggaar FP; Ten Kate FJ; Posthuma G; Souza RF; de Haan J; van Baal JW
    J Gastrointestin Liver Dis; 2016 Sep; 25(3):273-82. PubMed ID: 27689189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A population-based study of IGF axis polymorphisms and the esophageal inflammation, metaplasia, adenocarcinoma sequence.
    McElholm AR; McKnight AJ; Patterson CC; Johnston BT; Hardie LJ; Murray LJ;
    Gastroenterology; 2010 Jul; 139(1):204-12.e3. PubMed ID: 20403354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoid-induced TNFR family-related receptor (GITR)-expression in tumor infiltrating leucocytes (TILs) is associated with the pathogenesis of esophageal adenocarcinomas with and without Barrett's mucosa.
    von Rahden BH; Kircher S; Kafka M; Stuermer L; Reiber C; Gattenlöhner S; Germer CT; Grimm M
    Cancer Biomark; 2010; 7(6):285-94. PubMed ID: 21694467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
    Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haplotypes of the IL-1 gene cluster are associated with gastroesophageal reflux disease and Barrett's esophagus.
    Izakovicova Holla L; Borilova Linhartova P; Hrdlickova B; Marek F; Dolina J; Rihak V; Kala Z
    Hum Immunol; 2013 Sep; 74(9):1161-9. PubMed ID: 23806268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression, localization and polymorphisms of the nuclear receptor PXR in Barrett's esophagus and esophageal adenocarcinoma.
    van de Winkel A; Menke V; Capello A; Moons LM; Pot RG; van Dekken H; Siersema PD; Kusters JG; van der Laan LJ; Kuipers EJ
    BMC Gastroenterol; 2011 Oct; 11():108. PubMed ID: 21977915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.